Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Statins may affect prostate cancer microenvironment

Allott E et al. AUA 2018 (annual meeting of the American Urological Association), Abstract MP21-01.

Publish date:: June 11, 2018

Key clinical point: Researchers hope that genetic analyses could eventually point to prostate cancer patients who might benefit from statin use.

Major finding: Long-term statin users had lower odds of having a pTEN-null tumor (hazard ratio, 0.42), which is associated with worse outcomes.

Study details: Retrospective analysis of 5,792 diagnoses of prostate cancer among 44,076 men.

Disclosures: The study was funded by the Irish Cancer Society, the John Fitzpatrick Fellowship, and the National Cancer Institute. Dr. Allott reported no relevant financial relationships.

Source: Allott E et al. AUA 2018, Abstract MP21-01.

Citation:

Allott E et al. AUA 2018 (annual meeting of the American Urological Association), Abstract MP21-01.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Genitourinary Cancer

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Focal radiation boost nets better outcomes in prostate cancer,

Fear of recurrence highly prevalent in RCC survivors,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,